Martin H. Jr. Huber
CIK 1653276 · President, CEO · last filed 2026-05-22
Martin H. Jr. Huber is a President, CEO who has filed 44 SEC Form 4 insider transactions across 5 companies since 2015. The most recent filing, for ACTU, was dated May 22, 2026. Across all open-market trades the lifetime net is −$805.0K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $2.0M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$2.02M
5
44
-$805.0K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ACTU | Director | — | $1.06 | — | $0 | 1 | 2026-05-22 |
| SNDX | Director | 103,000 | $19.63 | $2.02M | $45.0K | 7 | 2026-02-06 |
| Mersana Therapeutics, Inc. (MRSN) Delisted | President, CEO | 0 | $29.08 | $0 | -$106.1K | 15 | 2026-01-06 |
| XLO | PRESIDENT AND HEAD OF R&D | — | $9.15 | — | $0 | 6 | 2023-08-18 |
| TESARO, Inc. (TSRO) Delisted | SVP & Chief Medical Officer | 0 | — | — | -$743.9K | 14 | 2019-01-22 |
Recent Filings
44 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-05-22 | ACTU | Grant (A) | — | $0 | EDGAR |
| 2026-02-06 | SNDX | Grant (A) | +24,000 | $0 | EDGAR |
| 2026-01-06 | Mersana Therapeutics, Inc. (MRSN) Delisted | Mixed | −9,573 | $0 | EDGAR |
| 2025-09-15 | Mersana Therapeutics, Inc. (MRSN) Delisted | Mixed | +4,658 | -$14.7K | EDGAR |
| 2025-05-19 | SNDX | Buy (P) | +5,000 | $45.0K | EDGAR |
| 2025-02-07 | SNDX | Grant (A) | +25,000 | $0 | EDGAR |
| 2025-01-17 | Mersana Therapeutics, Inc. (MRSN) Delisted | Mixed | +6,548 | -$2.6K | EDGAR |
| 2024-09-13 | Mersana Therapeutics, Inc. (MRSN) Delisted | Mixed | +116,327 | -$88.7K | EDGAR |
| 2024-09-13 | Mersana Therapeutics, Inc. (MRSN) Delisted | Notice (144) | −50,423 | -$89.2K | EDGAR |
| 2024-02-09 | SNDX | Grant (A) | +17,000 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.